Navigation Links
New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology
Date:10/26/2010

BEDMINSTER, N.J., Oct. 26 /PRNewswire/ -- Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, announced today that an analysis of two pivotal safety and efficacy studies of CAMBIA™ (diclofenac potassium for oral solution) will be presented at the 4th World Congress on Controversies in Neurology Conference (CONy) in Barcelona, Spain.

The new analysis will be presented in a poster (#23) entitled, "Rapid and Sustained Improvement in Migraine Symptoms with a New Powdered Formulation of Diclofenac Potassium for Oral Solution: Results from 2 Randomized Controlled Clinical Trials," and will be presented on Saturday, October 30, 2010 from 7:30 - 8:30 CEST by Alan Rapoport, MD of the David Geffen School of Medicine at University of California, Los Angeles.

About CAMBIA

CAMBIA, a novel, water-soluble, buffered diclofenac potassium powder, is the only prescription non-steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine.  Engineered using Dynamic Buffering Technology™ (DBT), a patented absorption-enhancing technology developed by APR Applied Pharma Research S.A., CAMBIA is specifically designed for fast, effective relief from the symptoms of migraine. CAMBIA enters the bloodstream quickly and readily achieves peak plasma concentrations, providing pain relief in fifteen minutes for some patients. For more information, please visit www.cambiarx.com.

About Nautilus Neurosciences, Inc.

Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the health care community with medically relevant products and services that directly benefit those affected by neurologic disorders.  Nautilus is backed by Tailwind Capital and Galen Partners.  For more information, please visit www.nautilusneurosciences.com.


'/>"/>
SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Publicis Groupe customer engagement agency ... and Healthcare Industry Group Leader, has been featured in ... most inspiring people in the life-sciences industry. Those chosen ... development, marketing, technology, creativity, strategy and medicine. ... partner in its leading Rosetta Consulting practice. In 2012, ...
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... Brazil and ... and commonly prescribe long-acting beta-agonist (LABA)- and long-acting ... so within current severe cost/coverage constraints. Therefore, new ... expected to launch in these countries—which will considerably ...
(Date:8/21/2014)... 21, 2014 /PRNewswire-iReach/ -- ScriptPro has been certified ... its Common Security Framework (CSF). According to ... Manager, "We appreciate this rigorous, top-to-bottom audit. Security-minded ... this certification signifies. Our business partners need to ... CSF CERTIFICATION PROCESS: ScriptPro,s internal security processes and ...
Breaking Medicine Technology:Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2
... Johnson & Johnson (NYSE: JNJ ) today ... & Diagnostics (MD&D) and Sheri McCoy, currently Worldwide Chairman, ... Committee and join William C. Weldon, Chairman of the ... of the Chairman.  Both appointments are effective January 3, ...
... LAKE FOREST, Ill., Dec. 15, 2010 RoundTable ... focused exclusively on the healthcare industry, announced today ... to sell one of its portfolio companies, Clinical ... private investment firm representing Pritzker family interests.  Terms ...
Cached Medicine Technology:Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 3RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2
(Date:8/22/2014)... growth factor receptor (EGFR) mutations found in the circulating ... non-small cell lung cancer (NSCLC) patients correlates well with ... EGFR tyrosine kinase inhibitor (TKI) therapy is approved for ... the standard for determining mutation status is with DNA ... or not available. A more abundant and less invasive ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Advancements ... for some clinical applications due to their cost-effectiveness, ... emerging innovations in ultrasound, such as the evolution ... expected to keep the market moving throughout 2014 ... mobility can enhance not only the point-of-care (POC) ...
(Date:8/22/2014)... August 22, 2014 CarePoint Health ... in Internal Medicine, Geriatrics, Hospice and Palliative Care, ... Health Medical Group. Their system welcomes Dr. Reisner ... experienced physicians comprise CarePoint Health Medical Group, a ... Hudson County, representing a wide range of specialties. ...
(Date:8/22/2014)... NJ. August 22, 2014. A new study ... persons with multiple sclerosis (MS) may be able ... The study was epublished ahead of print on ... Helen Genova, Hali Griswold, Nancy D. Chiaravalloti & ... persons with multiple sclerosis doi: 10.3233/NRE-141113). Self-awareness is ...
(Date:8/22/2014)... NEWPORT, RI Newport Hospital has again attained ... Nurses Credentialing Center,s (ANCC) Magnet Recognition Program. Considered ... hospital credentialing program recognizes nursing excellence and professionalism. ... nursing care. The unanimous decision to redesignate Newport ... to rigorous national standards of nursing practice. , ...
Breaking Medicine News(10 mins):Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2
... released the following statement on President Obama,s nomination of ... of Health and Human Services: "Governor Sebelius is ... health care access for children and to provide Kansans ... health care issues and their impact on our workers ...
... Aflac Incorporated (NYSE: AFL ) announced today that ... Annual Institutional Investors Conference. Sr. Vice President of Investor Relations ... is scheduled to make a presentation on March 9 at ... Janke will discuss the company,s outlook for 2009 and its ...
... March 2 Did you know that in ... five times more often and is six times ... are more eye-opening facts to share about this ... at: http://inr.mediaseed.tv/oneClip_C/?feed=pnskfD12vWjRAu2ArGmCrdet11lZRHEf Registered journalists can access video, ...
... A new study in the online issue of ... medications can work well among certain HIV patients who ... at higher risk for cardiovascular disease in part due ... of certain antiretroviral therapies, researchers now have evidence that ...
... week away, study finds, , , MONDAY, March 2 (HealthDay News) ... children with mild persistent asthma begin to show dramatic changes ... March issue of Pediatrics reports that just seven ... for a rural area, airway inflammation went down and lung ...
... cites association on GMPs and adverse event reportingWASHINGTON, ... the U.S. Government Accountability Office (GAO) of a ... supplements, the Natural Products Association (NPA) released the ... Seckman."The Natural Products Association appreciates having the opportunity ...
Cached Medicine News:Health News:Aflac Incorporated To Present at the Raymond James 30th Annual Institutional Investors Conference 2Health News:Largest Study to Date Compares Cholesterol Treatment in HIV Patients & Patients Without HIV Infection 2Health News:Largest Study to Date Compares Cholesterol Treatment in HIV Patients & Patients Without HIV Infection 3Health News:Largest Study to Date Compares Cholesterol Treatment in HIV Patients & Patients Without HIV Infection 4Health News:City Kids Find the Breathin' Is Easier Elsewhere 2Health News:City Kids Find the Breathin' Is Easier Elsewhere 3Health News:Natural Products Association Comments on New GAO Report on Regulation of Dietary Supplements 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: